arrow
E

Elgene Lim

St Vincent's Clinical School
H指数:53
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MDM2 inhibition restores p53 function to overcome dual endocrine and CDK4/6 inhibitor resistance in ER+ breast cancer

MDM2抑制通过恢复p53功能克服ER+乳腺癌对内分泌和CDK4/6抑制剂的联合耐药

2026-08-280
OA
Rb-driven transcription limits its tumour-suppressive effects in breast cancer

Rb驱动的转录限制其在乳腺癌中的肿瘤抑制作用

Nature
IF48.5
2026-08-120
OA
Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling

内分泌疗法对乳腺癌的重编程通过上调P-Rex1/Rac1信号通路促进转移性逃逸

2026-05-110
OAAI
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2− locally-advanced or metastatic breast cancer

腔内细胞系丢失驱动经治ER+ HER2−局部晚期或转移性乳腺癌对下一代ERα拮抗剂的耐药性

2026-04-010
OAAI
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial

Imlunestrant与或不与Abemaciclib联用治疗晚期乳腺癌:来自Ⅲ期EMBER-3试验的更新疗效结果

2025-12-120
OAAI
Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor-and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease

68Ga-NeoB PET/CT在雌激素受体和孕激素受体阳性乳腺癌患者转移性疾病分期或再分期中的诊断潜力

2025-03-270
PRE
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer
2024-10-020
PRE
Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
2024-05-021
PRE
Capivasertib plus cyclindependent kinase 4/6 inhibitor and fulvestrant in hormone receptorpositive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello292
2024-05-020
PRE
Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism

肿瘤生物力学通过重新连接脂肪酸代谢改变三阴性乳腺癌的转移扩散

2024-04-112
OA